Cargando…

Differential and Predictive Value of Galectin-3 and Soluble Suppression of Tumorigenicity-2 (sST2) in Heart Failure with Preserved Ejection Fraction

BACKGROUND: Galectin-3 and soluble suppression of tumorigenicity-2 (sST2) are promising biomarkers of cardiac fibrosis and ventricular remodeling. The purpose of this study was to investigate the diagnostic and predictive value of galectin-3 and sST2 for use in patients who have heart failure with p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cui, Yameng, Qi, Xin, Huang, Anan, Li, Jiao, Hou, Wenguang, Liu, Keqiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2018
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069579/ https://www.ncbi.nlm.nih.gov/pubmed/30039808 http://dx.doi.org/10.12659/MSM.908840

Ejemplares similares

Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction
Publicado: (2017)

Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction
por: AbouEzzeddine, Omar F., et al.
Publicado: (2017)

A meta-analysis of soluble suppression of tumorigenicity 2 (sST2) and clinical outcomes in pulmonary hypertension
por: Luk, King Sum, et al.
Publicado: (2017)

Reference interval and the role of soluble suppression of tumorigenicity 2 (sST2) in subclinical cardiac dysfunction at health checkups
por: Nah, Eun‐Hee, et al.
Publicado: (2020)

Soluble suppression of tumorigenicity 2 (sST2) for predicting disease severity or mortality outcomes in cardiovascular diseases: A systematic review and meta-analysis
por: Ip, Christina, et al.
Publicado: (2021)

Value of increased soluble suppressor tumorigenicity biomarker 2 (sST2) on admission as an indicator of severity in patients with COVID-19
por: Arnaldos-Carrillo, María, et al.
Publicado: (2023)

Diagnostic and prognostic value of serum soluble suppression of tumorigenicity-2 in heart failure with preserved ejection fraction: A systematic review and meta-analysis
por: Shi, Yujiao, et al.
Publicado: (2022)

Comparison of predictive value of NT-proBNP, sST2 and MMPs in heart failure patients with different ejection fractions
por: Pan, Wei, et al.
Publicado: (2020)

Effects of liraglutide vs. lifestyle changes on soluble suppression of tumorigenesis-2 (sST2) and galectin-3 in obese subjects with prediabetes or type 2 diabetes after comparable weight loss
por: Simeone, Paola, et al.
Publicado: (2022)

The prognostic value of sST2 and galectin-3 considering different aetiologies in non-ischaemic heart failure
por: Binas, David, et al.
Publicado: (2018)

Soluble ST2 and Galectin-3 and Progression of CKD
por: Alam, Mariam L., et al.
Publicado: (2018)

Galectin-3 and sST2 as Prognosticators for Heart Failure Requiring Extracorporeal Life Support: Jack n’ Jill
por: Bi, Jianli, et al.
Publicado: (2021)

N-Terminal Pro Brain Natriuretic Peptide, sST2, and Galectin-3 Levels in Breast Cancer Survivors
por: Patel, Shruti Rajesh, et al.
Publicado: (2021)

Galectin-3 and sST2: associations to the echocardiographic markers of the myocardial mechanics in systemic sclerosis – a pilot study
por: Vértes, Vivien, et al.
Publicado: (2022)

Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction
por: de Boer, Rudolf A, et al.
Publicado: (2011)

Diagnostic Value of Serum Concentration of Galectin-3 in Patients With Heart Failure With Preserved Ejection Fraction
por: Jiang, Jing, et al.
Publicado: (2022)

Suppression of Tumourigenicity 2 in Heart Failure With Preserved Ejection Fraction
por: Zach, Veronika, et al.
Publicado: (2020)

Multi-marker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis
por: Kim, Hanah, et al.
Publicado: (2017)

Evaluation of Galectin-3 as a Novel Diagnostic Biomarker in Patients with Heart Failure with Preserved Ejection Fraction
por: Kanukurti, Jyothirmayi, et al.
Publicado: (2020)

Clinical Implications of Plasma Galectin-3 in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis
por: Shi, Yujiao, et al.
Publicado: (2022)

Prognostic Value of sST2 in Heart Failure
por: Sciatti, Edoardo, et al.
Publicado: (2023)

Soluble Suppression of Tumorigenicity 2 and Echocardiography in Sepsis
por: Yang, Hyun Suk, et al.
Publicado: (2016)

Prognostic value of soluble suppression of tumorigenesis-2 (sST2) for cardiovascular events in coronary artery disease patients with and without diabetes mellitus
por: Li, Man, et al.
Publicado: (2021)

Association of Soluble Suppression of Tumorigenesis 2 (sST2) With Platelet Activation, Monocyte Tissue Factor and Ischemic Outcomes Following Angioplasty and Stenting
por: Stojkovic, Stefan, et al.
Publicado: (2020)

Increased ratio of sST2/LVMI predicted cardiovascular mortality and heart failure rehospitalization in heart failure with reduced ejection fraction patients: a prospective cohort study
por: Li, Fuhai, et al.
Publicado: (2021)

The IL-33/sST2 Axis in Thromboangiitis Obliterans
por: Sharebiani, Hiva, et al.
Publicado: (2020)

Sex and age differences in sST2 in cardiovascular disease
por: Beetler, Danielle J., et al.
Publicado: (2023)

sST2 and Heart Failure—Clinical Utility and Prognosis
por: Dudek, Magdalena, et al.
Publicado: (2023)

Cardiac Biomarkers in the Emergency Department: The Role of Soluble ST2 (sST2) in Acute Heart Failure and Acute Coronary Syndrome—There is Meat on the Bone
por: Aleksova, Aneta, et al.
Publicado: (2019)

Soluble IL-33 receptor sST2 inhibits colorectal cancer malignant growth by modifying the tumour microenvironment
por: Akimoto, Miho, et al.
Publicado: (2016)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Heart failure with preserved ejection fraction
por: ElGuindy, Ahmed, et al.
Publicado: (2012)

The Association of Serum IL-33 and sST2 with Breast Cancer
por: Yang, Zhi-Ping, et al.
Publicado: (2015)

Serum sST2 levels predict severe exacerbation of asthma
por: Watanabe, Masato, et al.
Publicado: (2018)

Prognostic value of soluble ST2 biomarker in heart failure patients with reduced ejection fraction – A multicenter study
por: Bahuleyan, C.G., et al.
Publicado: (2018)

Soluble ST2 and Galectin-3: What We Know and Don’t Know Analytically
por: Mueller, Thomas, et al.
Publicado: (2016)

Personalized Management for Heart Failure with Preserved Ejection Fraction
por: Lin, Chang-Yi, et al.
Publicado: (2023)

Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Failure
por: Huang, Dong-Hui, et al.
Publicado: (2016)

Critical roles of interleukin-33/suppression of tumorigenicity 2 (IL-33/ST2) in pulmonary disorders
por: Xu, Jiao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5ai684jlu15c17qf8b1p06p2o1